News
Effective April 1, 2021: Pharmacy and Biopharmacy Policies
Date: 01/26/21
Superior HealthPlan has created a new policy and revised existing pharmacy and biopharmacy policies to ensure medical necessity review criteria is current and appropriate for members and the scope of services provided. As a result the following policies have been created, revised or retired:
Policy | Applicable Products | New Policy Overview or Updated Policy Revisions |
|---|---|---|
Stiripentol (Diacomit) (CP.PMN.184) | Ambetter | Policy updates include:
|
Fenfluramine (Fintepla) (CP.PMN.246) | Ambetter | Policy updates include:
|
To review all Clinical policies, please visit Superior’s Clinical, Payment & Pharmacy Policies webpage.
Prior to updates, pharmacy and biopharmacy clinical policies are reviewed and approved by the Pharmacy and Therapeutics (P&T) Committee.
For questions or additional information, please contact Superior’s Pharmacy Department at 1-800-218-7453, ext. 22272.